Breakthrough, novel TECHNOLOGY meets unrivaled development potential
Artiam Bio, Inc. is a biotechnology company that is developing refined type 1 cannabinoid receptor (CB1) antagonists to treat significant diseases. We are accelerating innovation to bring safe and effective treatment options.
We are focused on leveraging our core competency in cannabinoid receptor biology to develop novel, small molecule drugs to help people whose lives are dramatically affected by severe diseases including non-alcoholic steatohepatitis (NASH), Prader Willi Syndrome (PWS), and Cannabis Use Disorder (CUD).
Target indications with 30 million + patients in USA
Patented portfolio of 400+ small molecules
Clinically proven receptor being targeted with de-risked strategy
Potential revenue >$10 billion for all indications
Follow-on indications in areas of high unmet need and growth
Artiam Bio: From pre-clinical advancements to real-world applications
We seek to bridge existing gaps through innovation and an ambitious commitment to superior science that will translate our pre-clinical advancements into real-world applications. We are on a mission to provide targeted therapies and innovative treatment options for non-alcoholic steatohepatitis (NASH), cannabis use disorder (CUD) and Prader-Willi Syndrome (PWS) using unmatched, clinically proven technologies.
Non-Alcoholic Steatohepatitis (NASH)
Cannabis Addiction / Overdose (CUD)
Prader-Willi Syndrome (PWS)
Learn More About Our Targeted Solutions
Type 1 Cannabinoid Receptor (CB1) Antagonists: A pipeline of promising therapeutics
Blockade of CB1 activity is a promising strategy based on both pre-clinical and clinical evidence. By minimizing the risks associated with earlier evolutions of CB1 antagonists, our best-in-class compounds have the unprecedented potential to deliver life-altering outcomes without mind-altering adverse effects.